Sequenta, Inc.’s Clonosight Test To Be Used By The Dana-Farber Cancer Institute/Acute Lymphoblastic Leukemia (ALL) Consortium
Published: Feb 25, 2014
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta, Inc. today announced that the DFCI/ALL Consortium will utilize the ClonoSIGHT™ test, the first sequencing-based test for minimal residual disease (MRD) in lymphoid cancers, for clinical care of children with ALL.
Help employers find you! Check out all the jobs and post your resume.